{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "xiaomei li"}, {"accession": "MS:1000589", "name": "contact email", "value": "xiaomei_li@ptm-biolab.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "PTM Biolabs lnc."}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Kangdong Liu"}, {"accession": "MS:1000589", "name": "contact email", "value": "kdliu@zzu.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-01.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-02.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-03.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-04.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-05.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_Ctrl-06.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-01.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-02.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-03.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-04.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-05.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/rep1_71203LQ_LD600-06.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824/txt_Ctrl_LD600.zip"}], "description": "The high recurrence rate and poor survival prospects of esophageal squamous cell carcinoma (ESCC) patients after treatment make the ongoing research on chemoprevention drugs for ESCC particularly important. In helping to solve this problem, we screened a large number of FDA-approved drugs and found that levodopa, a drug used to treat Parkinson\u2019s disease, has an inhibitory effect on the growth of ESCC cells. To elucidate the molecular mechanisms, we applied mass spectrometry to investigate the anti-tumor activity of levodopa on ESCC. The results suggest that levodopa can down-regulate oxidative phosphorylation, non-alcoholic fatty liver disease (NAFLD) and parkinson disease pathways. SDHD, NDUFS4 and MT-CO3, major respiratory compounds in the mitochondria, were involved in these pathways. Down-regulation of these proteins is associated with mitochondrial dysfunction. Western blotting and immunofluorescence results confirmed the authenticity of proteomics data. Cell viability assay revealed that mitochondrial activity had been suppressed after levodopa treatment. Mitochondrial membrane potential reduction was detected by JC-1 and TMRE assays. And transmission electron microscope (TEM) analysis indicated that mitochondrial morphology changed. Taken together, levodopa inhibits the growth of ESCC through restraining the mitochondria.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD013824"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD013824"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD013824"}], "instruments": [{"accession": "MS:1001911", "name": "Q Exactive"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Esophageal squamous cell carcinoma (ESCC), Levodopa, Chemoprevention, Mitochondria"}], "modifications": [{"accession": "MS:1002864", "name": "No PTMs are included in the dataset"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "33101026"}, {"accession": "MS:1002866", "name": "Reference", "value": "Li Z, Li X, He X, Jia X, Zhang X, Lu B, Zhao J, Lu J, Chen L, Dong Z, Liu K, Dong Z. Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma. Front Pharmacol. 2020 11:568459"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Proteomics reveals the inhibitory mechanism of Levodopa against esophageal squamous cell carcinoma"}